참고문헌
- A. C. Porter and R. R. Vaillancourt, Tyrosine Kinase Receptor-activated Signal Transduction Pathways Which Lead to Oncogenesis, Oncogene, 17, 1343 (1998) https://doi.org/10.1038/sj.onc.1202171
- P. Blume-Jensen and Tony Hunter, Oncogenic Kinase Signalling, Nature, 411, 355 (2001) https://doi.org/10.1038/35077225
- M. W. Deininger and B. J. Druker, Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib, Pharmacol Rev., 55, 401 (2003) https://doi.org/10.1124/pr.55.3.4
- D. Raben, B. A. Helfrich, D. Chan, G. Johnson, and P. A. Bunn, Jr., ZD1839, A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Alone and in Combination with Radiation and Chemotherapy as a New Therapeutic Strategy in Non-small Cell Lung Cancer, Semin. Oncol., 29 (Supplement 4), 37 (2002)
- R. Perez-Soler, A. Chachoua, L. A. Hammond, E. K. Rowinsky, M. Huberman, D. Karp, J. Rigas, G. M. Clark, P. Santabárbara, and P. Bonomi, Determinants of Tumor Response and Survival with Erlotinib in Patients with Non—Small-Cell Lung Cancer, J. Clin. Oncol., 22, 3238 (2004) https://doi.org/10.1200/JCO.2004.11.057
- S. A. Thomas, T. Li, K. W. Woods, X. Song, G. Packard, J. P. Fisher, R. B. Diebold, X. Liu, Y. Shi, V. Klinghofer, E. F. Johnson, J. J. Bouska, A. Olson, R. Guan, S. R. Magnone, K. Marsh, Y. Luo, S. H. Rosenberg, V. L. Giranda, and Q. Li, Identification of a Novel 3,5-Disubstituted Pyridine as a Potent, Selective, and Orally Active Inhibitor of Akt1 Kinase, Bioorg. Med. Chem. Lett., 16, 3740 (2006) https://doi.org/10.1016/j.bmcl.2006.04.046
- Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Johns, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber, M. E. Duggan, and C. W. Lindsley, Discovery of 2,3,5-Trisubstituted Pyridine Derivatives as Potent Akt1 and Akt2 Dual Inhibitors, Bioorg. Med. Chem. Lett., 15, 905 (2005) https://doi.org/10.1016/j.bmcl.2004.12.062
- S. F. Barnett, D. Defeo-Jones, K. M. Haskell, H. E. Huber, D. D. Nahas, C. W. Lindsley, Z. Zhao, and G. D. Hartman, Method of Treating Cancer, WO 084473 (2003)
- K. Nakatani, D. A. Thompson, A. Barthel, H. Sakaue, W. Liu, R. J. Weigel, and R. A. Roth, Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines, J. Biol. Chem., 274, 21528 (1999) https://doi.org/10.1074/jbc.274.31.21528
- S. F. Barnett, M. T. Bilodeau, and C. W. Lindsley, The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress towards Target Validation, Curr. Top. Med. Chem., 5, 109 (2005) https://doi.org/10.2174/1568026053507714
- A. Bellacosa, C. C. Kumar, A. Di Cristofano, and J. R. Testa, Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting, Adv. Cancer. Res., 94, 29 (2005) https://doi.org/10.1016/S0065-230X(05)94002-5
- C. S. Mitsiades, N. Mitsiades, and M. Koutsilieris, The Akt Pathway: Molecular Targets for Anti-cancer Drug Development. Curr. Cancer Drug Targets, 4, 235 (2004) https://doi.org/10.2174/1568009043333032
- P. Blume-Jensen and T. Hunter, Oncogenic Kinase Signalling, Nature, 411, 355 (2001) https://doi.org/10.1038/35077225
- J. Chattopadhya and S. K. Basu, Synthesis and Antibacterial Activity of Some Quinoline and 1,8-Naphthyridine Derivatives, Indian J. Chem., 29B, 98 (1990)
- J. R. Maxwell, D. A. Wasdahl, A. C. Wolfson, and V. I. Stenberg, Synthesis and Evaluation of Furan, Thiophene, and Azole Bis[(carbamoyloxy)methyl] Derivatives as Potential Antineoplastic Agents, J. Med. Chem., 27, 1565 (1984) https://doi.org/10.1021/jm00378a007
- Y. Kihara, S. Kabashima, K. Uno, T. Okawara, T. Yamasaki, and M. Furukawa, Oxidative Heterocyclization Using Diethyl Azodicarboxylate, Synthesis, 1020 (1990)